SMALL INTESTINE: Edited by David S. SandersGrowth factors and their use in short bowelOke, Siddharthaa,b; Walter, Merlin N.M.c; Ansari, Taherac; Gabe, Simon M.a,b Author Information aSt. Mark's Hospital, Harrow bDepartment of Surgery and Cancer, Imperial College, London cNorthwick Park Institute for Medical Research, Harrow, Middlesex, United Kingdom Correspondence to Siddhartha Oke, MBBS, BSc (Hons), MRCP, St Mark's Hospital, Watford Road, Harrow HA1 3UJ, United Kingdom. E-mail: [email protected] Current Opinion in Gastroenterology: May 2017 - Volume 33 - Issue 3 - p 212-217 doi: 10.1097/MOG.0000000000000351 Buy Metrics Abstract Purpose of review To examine the most recent literature on the clinical trials associated with the relevant growth factors that have been of interest in the treatment of short bowel. Recent findings Short bowel is a rare but devastating condition that condemns patients to lifelong parenteral support. Historically, treatment options negating the need for parenteral support were limited. Therapeutic growth factor use is of interest, but the clinical trial data are inconclusive. The STEPS-2 trial was the first trial that showed a sustained positive effect of the growth factor glucagon-like peptide-2 (GLP-2). This led to a phase shift in the management of short bowel, with the US Food and Drug Administration approval of the GLP-2 analogue teduglutide in 2012. This review summarizes all the relevant clinical trials of growth factors in the treatment of short bowel. Summary GLP-2 has shown that growth factors can revolutionize the treatment of short bowel. Data however are lacking with regards to the solitary use of other factors. This review highlights the need for further work using the factors in combination as well as considering their use in novel methods for example in the field of regenerative medicine. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.